

# SENATE BILL 87

J1

(8lr0040)

## ENROLLED BILL

— Finance/Health and Government Operations —

Introduced by **Chair, Finance Committee (By Request – Departmental – Health)**

Read and Examined by Proofreaders:

\_\_\_\_\_  
Proofreader.

\_\_\_\_\_  
Proofreader.

Sealed with the Great Seal and presented to the Governor, for his approval this

\_\_\_\_\_ day of \_\_\_\_\_ at \_\_\_\_\_ o'clock, \_\_\_\_\_ M.

\_\_\_\_\_  
President.

### CHAPTER \_\_\_\_\_

1 AN ACT concerning

2 **Controlled Dangerous Substances – Registration, Schedules, Penalties, and**  
3 **Orders of Impoundment**

4 FOR the purpose of requiring a person to be registered by the Maryland Department of  
5 Health before the person transports a controlled dangerous substance into the State  
6 under certain circumstances; altering the lists of substances designated as controlled  
7 dangerous substances under certain schedules under the Maryland Controlled  
8 Dangerous Substances Act; authorizing the Department to impose a certain civil  
9 penalty for each violation of the Maryland Controlled Dangerous Substances Act;  
10 requiring the Department to pay a certain penalty imposed by the Department into  
11 the General Fund of the State; authorizing the Department to issue an order of  
12 impoundment and immediately impound certain bulk powders and chemicals under  
13 certain circumstances; applying certain procedural requirements for impounding  
14 certain drugs to the impoundment of certain bulk powders and chemicals;  
15 authorizing the Department to charge certain fees to recover certain costs; altering

---

#### EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

Underlining indicates amendments to bill.

~~Strike out~~ indicates matter stricken from the bill by amendment or deleted from the law by amendment.

*Italics* indicate opposite chamber/conference committee amendments.



1 certain required procedures relating to the destruction or transfer of impounded  
2 drugs and applying the procedures to impounded bulk powders and chemicals;  
3 requiring the Department to adopt certain regulations; altering a certain definition;  
4 and generally relating to controlled dangerous substances.

5 BY repealing and reenacting, with amendments,  
6 Article – Criminal Law  
7 Section 5–301 and 5–402 through 5–406  
8 Annotated Code of Maryland  
9 (2012 Replacement Volume and 2017 Supplement)

10 BY adding to  
11 Article – Criminal Law  
12 Section 5–908  
13 Annotated Code of Maryland  
14 (2012 Replacement Volume and 2017 Supplement)

15 BY repealing and reenacting, with amendments,  
16 Article – Health – General  
17 Section 21–1113  
18 Annotated Code of Maryland  
19 (2015 Replacement Volume and 2017 Supplement)

20 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,  
21 That the Laws of Maryland read as follows:

22 **Article – Criminal Law**

23 5–301.

24 (a) (1) Except as otherwise provided in this section, a person shall be  
25 registered by the Department before the person manufactures, distributes, or dispenses a  
26 controlled dangerous substance in the State **OR TRANSPORTS A CONTROLLED**  
27 **DANGEROUS SUBSTANCE INTO THE STATE.**

28 (2) The Department shall adopt regulations to carry out this subsection.

29 (b) An applicant must register separately each principal place of business or  
30 professional practice where the applicant manufactures, distributes, or dispenses a  
31 controlled dangerous substance.

32 (c) To the extent authorized by the registration and subject to subsection (b) of  
33 this section and this subtitle, a person registered by the Department under this subtitle  
34 may:

35 (1) possess, manufacture, distribute, or dispense controlled dangerous  
36 substances; and

1 (2) perform any activity listed in item (1) of this subsection to conduct  
2 research.

3 (d) A person need not register with the Department to possess a controlled  
4 dangerous substance while acting in the course of the person's business or profession if the  
5 person is:

6 (1) an agent or agent's employee of a registered manufacturer, distributor,  
7 or dispenser of a controlled dangerous substance;

8 (2) a common or contract carrier or warehouseman, or an employee of a  
9 common or contract carrier or warehouseman; or

10 (3) an ultimate user or person in possession of a controlled dangerous  
11 substance acting in good faith in accordance with a lawful order of an authorized provider.

12 (e) If the Department finds that a waiver is consistent with public health and  
13 safety, by regulation, the Department may waive the registration requirement for a  
14 manufacturer, distributor, or dispenser.

15 5-402.

16 (a) Schedule I consists of each controlled dangerous substance:

17 (1) listed in this section;

18 (2) added to Schedule I by the Department under § 5-202(b) of this title; or

19 (3) designated as a Schedule I controlled dangerous substance by the  
20 federal government unless the Department objects under § 5-202(f) of this title.

21 (b) **UNLESS SPECIFICALLY EXCEPTED UNDER THIS SUBTITLE OR LISTED IN**  
22 **ANOTHER SCHEDULE, ANY OF THE FOLLOWING OPIATES, INCLUDING THEIR**  
23 **ISOMERS, INCLUDING OPTICAL AND GEOMETRIC ISOMERS, ESTERS, ETHERS, SALTS,**  
24 **AND SALTS OF ISOMERS, ESTERS, AND ETHERS, WHENEVER THE EXISTENCE OF SUCH**  
25 **ISOMERS, ESTERS, ETHERS, OR SALTS IS POSSIBLE WITHIN THE SPECIFIC CHEMICAL**  
26 **DESIGNATION, ARE**

27 [(1) These] substances [are] listed in Schedule I:

28 (1) **ACETYL-ALPHA-METHYLFENTANYL;**

29 [(i)] (2) **acetylmethadol;**



- 1           **(23) DIMENOXADOL;**
- 2           [(xix)] **(24)** dimepheptanol;
- 3           [(xx)] **(25)** dimethylthiambutene;
- 4           [(xxi)] **(26)** dioxaphetyl butyrate;
- 5           [(xxii)] **(27)** dipipanone;
- 6           [(xxiii)] **(28)** ethylmethylthiambutene;
- 7           [(xxiv)] **(29)** etonitazene;
- 8           [(xxv)] **(30)** etoxeridine;
- 9           [(xxvi)] **(31)** furethidine;
- 10          [(xxvii)] **(32)**        hydroxypethidine;
- 11          [(xxviii)] **(33)**       ketobemidone;
- 12          [(xxix)] **(34)** levomoramide;
- 13          [(xxx)] **(35)** levophenacylmorphan;
- 14          **(36) 3-METHYLFENTANYL   (N-3-METHYL-1-(2-PHENYLETHYL)-4-**  
15 **PIPERIDYL-1-N-PHENYLPROPANAMIDE);**
- 16          **(37) 3-METHYLTHIOFENTANYL;**
- 17          [(xxxix)] **(38)** morpheridine;
- 18          **(39) MPPP (1-METHYL-4-PHENYL-4-PROPIONOXYPIPERIDINE);**
- 19          [(xxxix)] **(40)**        noracymethadol;
- 20          [(xxxix)] **(41)**        norlevorphanol;
- 21          [(xxxix)] **(42)**        normethadone;
- 22          [(xxxix)] **(43)** norpipanone;
- 23          **(44) PARA-FLUOROFENTANYL;**

1 **(45) PEPAP** **(1-(2-PHENETHYL)-4-PHENYL-4-**  
 2 **ACETOXYPIPERIDINE);**

3 [(xxxvi)] **(46)** phenadoxone;

4 [(xxxvii)] **(47)** phenampromide;

5 [(xxxviii)] **(48)** phenomorphan;

6 [(xxxix)] **(49)** phenoperidine;

7 [(xl)] **(50)** piritramide;

8 [(xli)] **(51)** proheptazine;

9 [(xlii)] **(52)** properidine;

10 [(xliii)] **(53)** propiram;

11 [(xliv)] **(54)** racemoramide; [and]

12 **(55) THIOFENTANYL;**

13 **(56) TILIDINE; AND**

14 [(xlv)] **(57)** trimeperidin.

15 [(2) Unless specifically excepted under this subtitle, an isomer, ester, ether,  
 16 or salt of a substance listed in this subsection or a salt of the isomer, ester, or ether is a  
 17 substance listed in Schedule I if the existence of the isomer, ester, ether, or salt is possible  
 18 within the specific chemical designation.]

19 (c) **UNLESS SPECIFICALLY EXCEPTED UNDER THIS SUBTITLE OR LISTED IN**  
 20 **ANOTHER SCHEDULE, ANY OF THE FOLLOWING OPIUM DERIVATIVES, INCLUDING**  
 21 **THEIR SALTS, ISOMERS, AND SALTS OF ISOMERS, WHENEVER THE EXISTENCE OF**  
 22 **SUCH SALTS, ISOMERS, OR SALTS OF ISOMERS IS POSSIBLE WITHIN THE SPECIFIC**  
 23 **CHEMICAL DESIGNATION, ARE SUBSTANCES LISTED IN SCHEDULE I:**

24 [(1) These opium derivatives are substances listed in Schedule I:

25 (i) **(1)** acetorphine;

26 (ii) **(2)** acetyldihydrocodeine;

- 1 [(iii) acetylocodone;]
- 2 [(iv)] (3) benzylmorphine;
- 3 [(v)] (4) codeine methylbromide;
- 4 [(vi)] (5) codeine-N-oxide;
- 5 [(vii) codoxime;]
- 6 [(viii)] (6) cyprenorphine;
- 7 [(ix)] (7) desomorphine;
- 8 [(x)] (8) dihydromorphine;
- 9 [(xi)] (9) drotebanol;
- 10 [(xii) ethylmorphine methyl iodide;]
- 11 [(xiii)] (10) etorphine (EXCEPT HYDROCHLORIDE SALT);
- 12 [(xiv) etorphine 3-methylether;]
- 13 [(xv)] (11) heroin;
- 14 [(xvi)] (12) hydromorphenol;
- 15 [(xvii)] (13) methyl-desorphine;
- 16 [(xviii) methyldihydromorphinone;]
- 17 (14) METHYLDIHYDROMORPHINE;
- 18 [(xix) methylhydromorphine;]
- 19 [(xx)] (15) morphine methylbromide;
- 20 [(xxi) morphine methylchloride;]
- 21 [(xxii)] (16) morphine methylsulfonate;
- 22 [(xxiii)] (17) morphine-N-oxide;
- 23 [(xxiv)] (18) myrophine;

- 1 [(xxv)] (19) nicocodeine;
- 2 [(xxvi) nicodicodine;]
- 3 [(xxvii)] (20) nicomorphine;
- 4 [(xxviii) norcodeine;]
- 5 [(xxix)] (21) normorphine;
- 6 [(xxx)] (22) pholcodine; and
- 7 [(xxxi)] (23) thebacon.

8 [(2) Unless specifically excepted under this subtitle, a salt, isomer, or salt  
9 of an isomer of a substance listed in this subsection is a Schedule I substance if the existence  
10 of the salt, isomer, or salt of an isomer is possible within the specific chemical designation.]

11 (d) **UNLESS SPECIFICALLY EXCEPTED UNDER THIS SUBTITLE OR LISTED IN**  
12 **ANOTHER SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION**  
13 **THAT CONTAINS ANY QUANTITY OF THE FOLLOWING HALLUCINOGENIC**  
14 **SUBSTANCES, OR THAT CONTAINS ANY OF ITS SALTS, ISOMERS, INCLUDING OPTICAL,**  
15 **POSITION, AND GEOMETRIC ISOMERS, OR SALTS OF ISOMERS, WHENEVER THE**  
16 **EXISTENCE OF SUCH SALTS, ISOMERS, OR SALTS OF ISOMERS IS POSSIBLE WITHIN**  
17 **THE SPECIFIC CHEMICAL DESIGNATION, IS A SUBSTANCE LISTED IN SCHEDULE I:**

18 [(1) A material, compound, mixture, or preparation that contains any of the  
19 following hallucinogenic or hallucinogenic-like substances is a substance listed in Schedule  
20 I:]

- 21 (1) ~~ALPHA-ETHYTRYPTAMINE~~ ALPHA-ETHYLTRYPTAMINE;
- 22 (2) 4-BROMO-2,5-DIMETHOXY-AMPHETAMINE;
- 23 (3) 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE;
- 24 (4) 2,5-DIMETHOXYAMPHETAMINE;
- 25 (5) 2,5-DIMETHOXY-4-ETHYLAMPHETAMINE (DOET);
- 26 (6) 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE  
27 (2C-T-7);
- 28 (7) 4-METHOXYAMPHETAMINE (PMA);



- 1           **(8) 5-METHOXY-3,4-METHYLENEDIOXY-AMPHETAMINE;**
- 2           **(9) 4-METHYL-2,5-DIMETHOXY-AMPHETAMINE;**
- 3           **(10) 3,4-METHYLENEDIOXY AMPHETAMINE;**
- 4           **(11) 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA);**
- 5           **(12) 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDA);**
- 6           **(13) N-HYDROXY-3,4-METHYLENEDIOXYAMPHETAMINE;**
- 7           **(14) 3,4,5-TRIMETHOXYAMPHETAMINE;**
- 8           **(15) 5-METHOXY-N, N-DIMETHYLTRYPTAMINE;**
- 9           **(16) ALPHA-METHYLTRYPTAMINE (AMT);**
- 10           **[(i)] (17) bufotenine;**
- 11           **[(ii)] (18) diethyltryptamine (DET);**
- 12           **[(iii)] (19) dimethyltryptamine (DMT);**
- 13           **[(iv) 4-methyl-2, 5-dimethoxyamphetamine;]**
- 14           **(20) 5-METHOXY-N, N-DIISOPROPYLTRYPTAMINE (5-MEO-DIPT);**
- 15           **[(v)] (21) ibogaine;**
- 16           **[(vi)] (22) lysergic acid diethylamide;**
- 17           **[(vii)] (23) marijuana;**
- 18           **[(viii)] (24) mescaline;**
- 19           **(25) PARAHEXYL;**
- 20           **[(ix)] (26) peyote (MEANING ALL PARTS OF THE PLANT**
- 21 **PRESENTLY CLASSIFIED BOTANICALLY AS LOPHOPHORA WILLIAMSII LEMAIRE,**
- 22 **WHETHER GROWING OR NOT, THE SEEDS THEREOF, ANY EXTRACT FROM ANY PART**
- 23 **OF SUCH PLANT, AND EVERY COMPOUND, MANUFACTURE, SALT, DERIVATIVE,**
- 24 **MIXTURE, OR PREPARATION OF SUCH PLANT, ITS SEEDS, OR EXTRACTS);**

- 1           **(27) N-ETHYL-3-PIPERIDYL BENZILATE;**
- 2           **(28) N-METHYL-3-PIPERIDYL BENZILATE;**
- 3           ~~[(x)]~~ **(29)** psilocybin;
- 4           ~~[(xi)]~~ **(30)** psilocyn;
- 5           ~~[(xii)]~~ **(31)** tetrahydrocannabinols;
- 6           ~~[(xiii)]~~ thiophene analog of phencyclidine;
- 7           (xiv) 2, 5-dimethoxyamphetamine;
- 8           (xv) 4-bromo-2, 5-dimethoxyamphetamine;
- 9           (xvi) 4-methoxyamphetamine;
- 10          (xvii) 3, 4-methylenedioxyamphetamine;
- 11          (xviii) 3, 4-methylenedioxymethamphetamine (MDMA);
- 12          (xix) 5-methoxy-3, 4-methylenedioxyamphetamine;
- 13          (xx) 3, 4, 5-trimethoxyamphetamine;
- 14          (xxi) N-methyl-3-piperidyl benzilate;
- 15          (xxii) N-ethyl-3-piperidyl benzilate;]
- 16                   ~~[(xxiii)]~~ **(32)**           **ETHYLAMINE ANALOG OF PHENCYCLIDINE**  
17 **(N-ethyl-1-phenylcyclohexylamine);**
- 18                   ~~[(xxiv)]~~ **(33)**           **PYRROLIDINE ANALOG OF PHENCYCLIDINE**  
19 **(1-(1-phenylcyclohexyl)-pyrrolidine);**
- 20                   ~~[(xxv)]~~ **(34)**           **THIOPHENE ANALOG OF PHENCYCLIDINE**  
21 **(1-(1-(2-thienyl)-cyclohexyl)-piperidine);**
- 22           ~~[(xxvi)]~~           1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
- 23           ~~[(xxvii)]~~           1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP);
- 24           ~~[(xxviii)]~~           3, 4-methylenedioxymethcathinone (methylone);]

- 1           **(35) 1-[1-(2-THIENYL) CYCLOHEXYL] PYRROLIDINE;**
- 2                   **[(xxix) (36) 3, 4-methylenedioxypropylvalerone (MDPV);**
- 3                   **[(xxx) (37) 4-methylmethcathinone (mephedrone);**
- 4                   **[(xxxii) (38) 4-methoxymethcathinone (methedrone);**
- 5           **(39) 2-(2,5-DIMETHOXY-4-ETHYLPHENYL) ETHANAMINE (2C-E);**
- 6           **(40) 2-(2,5-DIMETHOXY-4-METHYLPHENYL) ETHANAMINE (2C-D);**
- 7           **(41) 2-(4-CHLORO-2,5-DIMETHOXYPHENYL) ETHANAMINE (2C-C);**
- 8           **(42) 2-(4-IODO-2,5-DIMETHOXYPHENYL) ETHANAMINE (2C-I);**
- 9           **(43) 2-(4-ETHYLTHIO-2,5-DIMETHOXYPHENYL) ETHANAMINE**  
10 **(2C-T-2);**
- 11           **(44) 2-(4-ISOPROPYLTHIO)-2,5-DIMETHOXYPHENYL) ETHANAMINE**  
12 **(2C-T-4);**
- 13           **(45) 2-(2,5-DIMETHOXYPHENYL) ETHANAMINE (2C-H);**
- 14           ~~**(46) 2-(2,5-DIMETHOXYPHENYL) ETHANAMINE (2C-H);**~~
- 15           ~~**(47) (46) 2-(2,5-DIMETHOXY-4-(N)-PROPYLPHENYL) ETHANAMINE**~~  
16 **(2C-P);**
- 17           ~~**(48) (47) 3,4-METHYLENEDIOXYMETHCATHINONE (METHYLONE);**~~
- 18           ~~**(49) (48) (1-PENTYL-1H-INDOL-3-YL) (2,2,3,3-**~~  
19 **TETRAMETHYLCYCLOPROPYL) METHANONE (UR-144);**
- 20           ~~**(50) (49) [1-(5-FLUORO-PENTYL)-1H-INDOL-3-YL]**~~  
21 **(2,2,3,3-TETRAMETHYLCYCLOPROPYL) METHANONE (5-FLUORO-UR-144, XLR11);**
- 22           ~~**(51) (50) N-(1-ADAMANTYL)-1-PENTYL-1H-INDAZOLE-3-**~~  
23 **CARBOXAMIDE (APINACA, AKB48);**
- 24           ~~**(52) (51) QUINOLIN-8-YL 1-PENTYL-1H-INDOLE-3-CARBOXYLATE**~~  
25 **(PB-22);**

- 1                    ~~(53)~~ (52)    QUINOLIN-8-YL                    1-(5-FLUOROPENTYL)-1H  
2 -INDOLE-3-CARBOXYLATE (~~5-FLUORO-PB-22~~);
- 3                    ~~(54)~~ (53)    N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-(4-  
4 FLUOROBENZYL)-1H-INDAZOLE-3-CARBOXAMIDE (AB-FUBINACA);
- 5                    ~~(55)~~ (54)    N-(1-AMINO-3,            3-DIMETHYL-1-OXOBUTAN-2-YL)-1-  
6 PENTYL-1H-INDAZOLE-3-CARBOXAMIDE (ADB-PINACA);
- 7                    ~~(56)~~ (55)    2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-  
8 METHOXYBENZYL) ETHANAMINE (~~25I~~-NBOME);
- 9                    ~~(57)~~ (56)    2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-  
10 METHOXYBENZYL) ETHANAMINE (~~25C~~-NBOME);
- 11                   ~~(58)~~ (57)    2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-  
12 METHOXYBENZYL) ETHANAMINE (~~25B~~-NBOME);
- 13                   ~~(59)~~ (58)    MARIJUANA EXTRACT (MEANING AN EXTRACT CONTAINING  
14 ONE OR MORE CANNABINOIDS THAT HAS BEEN DERIVED FROM ANY PLANT OF THE  
15 GENUS CANNABIS, OTHER THAN THE SEPARATED RESIN, WHETHER CRUDE OR  
16 PURIFIED, OBTAINED FROM THE PLANT);
- 17                   ~~(60)~~ (59)    4-METHYL-N-ETHYLCATHINONE (4-MEC);
- 18                   ~~(61)~~ (60)    4-METHYL-ALPHA-PYRROLIDINOPROPIOPHENONE            (4-  
19 MEPPP);
- 20                   ~~(62)~~ (61)    ALPHA-PYRROLIDINOPENTIOPHENONE (A-PVP);
- 21                   ~~(63)~~ (62)    1-(1,3-BENZODIOXOL-5-YL)-2-(METHYLAMINO)    BUTAN-  
22 1-ONE (BUTYLONE);
- 23                   ~~(64)~~ (63)    2-(METHYLAMINO)-1-PHENYLPENTAN-1-ONE  
24 (PENTEDRONE);
- 25                   ~~(65)~~ (64)    1-(1,3-BENZODIOXOL-5-YL)-2-(METHYLAMINO) PENTAN-  
26 1-ONE (PENTYLONE);
- 27                   [(xxxii)        4-fluoromethmethcathinone (flephedrone);]
- 28                   ~~(66)~~ (65)    4-FLUORO-N-METHYLCATHINONE (FLEPHEDRONE);
- 29                   [(xxxiii) 3-fluoromethcathinone (3-FMC); and]

~~(67)~~ **(66)** 3-FLUORO-N-METHYLCATHINONE (3-FMC);

[(xxxiv)] ~~(68)~~ **(67)** cannabimimetic agents;

~~(69)~~ **(68)** 1-(NAPHTHALEN-2-YL)-2-(PYRROLIDIN-1-YL)PENTAN-1-  
ONE (NAPHYRONE); AND

~~(70)~~ **(69)** ALPHA-PYRROLIDINOBTIOPHENONE (A-PBP).

[(2) Unless specifically excepted under this subtitle, a salt, isomer, or salt of an isomer of a substance listed in this subsection is a substance listed in Schedule I if the existence of the salt, isomer, or salt of an isomer is possible within the specific chemical designation.]

**(E) UNLESS SPECIFICALLY EXCEPTED UNDER THIS SUBTITLE OR LISTED IN ANOTHER SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION THAT CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES, OR THAT CONTAINS THEIR SALTS, ISOMERS, OR SALTS OF ISOMERS, WHENEVER THE EXISTENCE OF SUCH SALTS, ISOMERS, OR SALTS OF ISOMERS IS POSSIBLE WITHIN THE SPECIFIC CHEMICAL DESIGNATION, IS A SUBSTANCE LISTED IN SCHEDULE I:**

**(1) 5-(1, 1-DIMETHYLHEPTYL)-2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-PHENOL (CP-47,497);**

**(2) 5-(1,1-DIMETHYLOCTYL)-2- [(1R,3S)3-HYDROXYCYCLOHEXYL]-PHENOL (CP-47,497 C8 HOMOLOGUE);**

**(3) 1-PENTYL-3-(1-NAPHTHOYL) INDOLE (JWH-018 AND AM678)**

**(4) 1-BUTYL-3-(1-NAPHTHOYL) INDOLE (JWH-073);**

**(5) 1-HEXYL-3-(1-NAPHTHOYL) INDOLE (JWH-019);**

**(6) 1-[2-(4-MORPHOLINYL)ETHYL]-3-(1-NAPHTHOYL) INDOLE (JWH-200);**

**(7) 1-PENTYL-3-(2-METHOXYPHENYLACETYL) INDOLE (JWH-250);**

**(8) 1-PENTYL-3-(1-(4-METHOXYNAPHTHOYL) INDOLE (JWH-081);**

**(9) 1-PENTYL-3-(4-METHYL-1-NAPHTHOYL) INDOLE (JWH-122);**

**(10) 1-PENTYL-3-(4-CHLORO-1-NAPHTHOYL) INDOLE (JWH-398);**

- 1           **(11) 1-(5-FLUOROPENTYL)-3-(1-NAPHTHOYL) INDOLE (AM2201);**  
2           **(12) 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL) INDOLE (AM694);**  
3           **(13) 1-PENTYL-3-[(4-METHOXY)-BENZOYL] INDOLE (SR-19 AND**  
4 **RCS-4);**  
5           **(14) 1-CYCLOHEXYLETHYL-3-(2-METHOXYPHENYLACETYL) INDOLE**  
6 **(SR-18 AND RCS-8); AND**  
7           **(15) 1-PENTYL-3-(2-CHLOROPHENYLACETYL) INDOLE (JWH-203).**

8           **[(e)] (F) UNLESS SPECIFICALLY EXCEPTED UNDER THIS SUBTITLE OR**  
9 **LISTED IN ANOTHER SCHEDULE, A MATERIAL, COMPOUND, MIXTURE, OR**  
10 **PREPARATION THAT CONTAINS ANY QUANTITY OF THE FOLLOWING SUBSTANCES**  
11 **HAVING DEPRESSANT EFFECTS ON THE CENTRAL NERVOUS SYSTEM, OR THAT**  
12 **CONTAINS ITS SALTS, ISOMERS, OR SALTS OF ISOMERS, WHENEVER THE EXISTENCE**  
13 **OF SUCH SALTS, ISOMERS, OR SALTS OF ISOMERS IS POSSIBLE WITHIN THE SPECIFIC**  
14 **CHEMICAL DESIGNATION, IS A SUBSTANCE LISTED IN SCHEDULE I:**

15           **[(1) Unless specifically excepted under this subtitle or listed in another**  
16 **schedule, a material, compound, mixture, or preparation that contains any quantity of the**  
17 **following substances having a depressant effect on the central nervous system is a**  
18 **substance listed in Schedule I:**

- 19           **(i) (1) mecloqualone;**  
20           **[(ii) (2) methaqualone; and**  
21           **(3) GAMMA-HYDROXYBUTYRIC ACID.**

22           **[(iii) a salt, isomer, or salt of an isomer of a substance listed in this**  
23 **paragraph if the existence of the salt, isomer, or salt of an isomer is possible within the**  
24 **specific chemical designation.**

25           **(2) Any material, compound, mixture, or preparation that contains any of**  
26 **the following substances is a substance listed in Schedule I:**

- 27           **(i) 3-methylfentanyl (N-3-methyl-1-(2-phenylethyl)-4-**  
28 **piperidyl-1-N-phenylpropanamide), its optical and geometric isomers, salts, and salts of**  
29 **isomers;**  
30           **(ii) acetyl-alpha-methylfentanyl;**  
31           **(iii) alpha-methylthiofentanyl;**

- 1 (iv) benzylfentanyl;
- 2 (v) beta-hydroxy-3-methylfentanyl;
- 3 (vi) beta-hydroxyfentanyl;
- 4 (vii) thenylfentanyl;
- 5 (viii) thiofentanyl; and
- 6 (ix) 3-methylthiofentanyl.]

7 (G) UNLESS SPECIFICALLY EXCEPTED OR LISTED IN ANOTHER SCHEDULE,  
8 ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARATION THAT CONTAINS ANY  
9 QUANTITY OF THE FOLLOWING SUBSTANCES HAVING A STIMULANT EFFECT ON THE  
10 CENTRAL NERVOUS SYSTEM, OR THAT CONTAINS ITS SALTS, ISOMERS, OR SALTS OF  
11 ISOMERS, IS A SUBSTANCE LISTED IN SCHEDULE I:

- 12 (1) AMINOREX;
- 13 (2) N-BENZYLPIPERAZINE;
- 14 (3) CATHINONE;
- 15 (4) FENETHYLLINE;
- 16 (5) METHCATHINONE;
- 17 (6) 4-METHYLAMINOREX;
- 18 (7) (±)CIS-4-METHYLAMINOREX;
- 19 (8) N-ETHYLAMPHETAMINE; AND
- 20 (9) N, N-DIMETHYLAMPHETAMINE.

21 [(f)] (H) (1) In this subsection:

- 22 (i) “controlled dangerous substance analogue” means a substance:
- 23 1. that has a chemical structure substantially similar to the  
24 chemical structure of a controlled dangerous substance listed in Schedule I or Schedule II;  
25 and

1                                   2.     that has a stimulant, depressant, or hallucinogenic effect  
2 on the central nervous system that is substantially similar to or greater than the stimulant,  
3 depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous  
4 substance listed in Schedule I or Schedule II; but

5                                   (ii)   “controlled dangerous substance analogue” does not include:

6                                   1.     a controlled dangerous substance;

7                                   2.     a substance for which there is an approved new drug  
8 application; or

9                                   3.     a substance exempted for investigational use under § 506  
10 of the Federal Food, Drug, and Cosmetic Act.

11                               (2)   To the extent intended for human consumption, each controlled  
12 dangerous substance analogue is a substance listed in Schedule I.

13                   **[(g)] (I)**     The Department may not add a substance to Schedule I under § 5–202  
14 of this title unless the Department finds:

15                               (1)   a high potential for abuse of the substance;

16                               (2)   no accepted medical use in the United States for the substance; and

17                               (3)   a lack of accepted safety for use of the substance under medical  
18 supervision.

19 5–403.

20                   (a)   Schedule II consists of each controlled dangerous substance:

21                               (1)   listed in this section;

22                               (2)   added to Schedule II by the Department under § 5–202(b) of this title;  
23 or

24                               (3)   designated as a Schedule II controlled dangerous substance by the  
25 federal government unless the Department objects under § 5–202(f) of this title.

26                   (b)   (1)   Unless the substance is listed in another schedule and except as  
27 provided in paragraph (2) of this subsection, opium and opiate, and a salt, compound,  
28 derivative, or preparation of opium or opiate is a substance listed in Schedule II, including:

29                               (i)   raw opium;

30                               (ii)  opium extracts;



1                   **(III) OPIUM FLUID EXTRACT;**

2                   [(iii)] **(IV)**    opium fluid;

3                   [(iv)] **(V)**     powdered opium;

4                   [(v)] **(VI)**     granulated opium;

5                   [(vi)] **(VII)**  tincture of opium;

6                   [(vii)] **(VIII)** codeine;

7                   **(IX) DEXTROPROPOXYHENE BULK (NONDOSAGE FORM);**

8                   **(X) DIHYDROETORPHINE;**

9                   [(viii)] **(XI)**  ethylmorphine;

10                  [(ix)] **(XII)**  etorphine hydrochloride;

11                  [(x)] **(XIII)** hydrocodone;

12                  [(xi)] **(XIV)** hydromorphone;

13                  [(xii)] **(XV)**  metopon;

14                  [(xiii)] **(XVI)** morphine;

15                  **(XVII) ORIPAVINE;**

16                  [(xiv)] **(XVIII)**    oxycodone;

17                  [(xv)] **(XIX)** oxymorphone; and

18                  [(xvi)] **(XX)**  thebaine.

19                  (2) Apomorphine, dextrorphan, nalbuphine, naloxone, and naltrexone, and  
20 their respective salts, are not substances listed in Schedule II.

21                  (3) Substances listed in Schedule II also include:

22                         (i)    except for the isoquinoline alkaloids of opium, a salt, compound,  
23 derivative, or preparation that is chemically equivalent or identical to a substance listed in  
24 paragraph (1) of this subsection;

- 1 (ii) opium poppy [and], poppy straw, **AND POPPY STRAW**  
 2 **CONCENTRATE;**
- 3 (iii) coca leaf;
- 4 (iv) cocaine, its salts, optical and geometric isomers, and salts of  
 5 isomers;
- 6 (v) ecgonine, its derivatives, their salts, isomers, and salts of  
 7 isomers; and
- 8 (vi) a compound, mixture, or preparation that contains any of the  
 9 substances listed in this section.
- 10 (4) A substance that is listed in Schedule II is included whether produced:
- 11 (i) directly or indirectly by extraction from substances of vegetable  
 12 origin;
- 13 (ii) independently by chemical synthesis; or
- 14 (iii) by a combination of extraction and chemical synthesis.
- 15 (c) (1) These opiates are substances listed in Schedule II:
- 16 **(I) ALFENTANIL;**
- 17 [(i)] **(II) alphaprodine;**
- 18 [(ii)] **(III) anileridine;**
- 19 [(iii)] **(IV) bezitramide;**
- 20 **(V) CARFENTANIL;**
- 21 [(iv)] **(VI) dihydrocodeine;**
- 22 [(v)] **(VII) diphenoxylate;**
- 23 **(VIII) ~~DROBINAL~~ DRONABINAL DRONABINOL (IN ORAL**  
 24 **SOLUTION);**
- 25 [(vi)] **(IX) fentanyl;**
- 26 [(vii)] **(X) isomethadone;**

- 1                    [(viii)] **(XI)** levoalphacetylmethadol;
- 2                    [(ix)] **(XII)** levomethorphan;
- 3                    [(x)] **(XIII)** levorphanol;
- 4                    [(xi)] **(XIV)** metazocine;
- 5                    [(xii)] **(XV)** methadone;
- 6                    [(xiii)] **(XVI)** methadone                    –                    intermediate,  
 7 4–cyano–2–dimethylamino–4, 4–diphenyl butane;
- 8                    [(xiv)] **(XVII)** moramide                    –                    intermediate,                    2–methyl–3–  
 9 morpholino–1, 1–diphenyl–propane–carboxylic acid;
- 10                    [(xv)] **(XVIII)** pethidine;
- 11                    [(xvi)] **(XIX)** pethidine                    –                    intermediate                    –                    A,  
 12 4–cyano–1–methyl–4–phenylpiperidine;
- 13                    [(xvii)] **(XX)** pethidine                    –                    intermediate                    –                    B,  
 14 ethyl–4–phenylpiperidine–4–carboxylate;
- 15                    [(xviii)] **(XXI)** pethidine                    –                    intermediate                    –                    C,  
 16 1–methyl–4–phenylpiperidine–4–carboxylic acid;
- 17                    [(xix)] **(XXII)** phenazocine;
- 18                    [(xx)] **(XXIII)** piminodine;
- 19                    [(xxi)] **(XXIV)** racemethorphan;
- 20                    [(xxii)] **(XXV)** racemorphan; [and]
- 21                    **(XXVI)**                    REMIFENTANIL;
- 22                    [(xxiii)] **(XXVII)** sulfentanil;
- 23                    **(XXVIII)**                    TAPENTADOL; AND
- 24                    **(XXIX)**                    THIAFENTANIL.

1           (2) Unless specifically excepted under this subtitle, an isomer, ester, ether,  
2 or salt of an opiate and a salt of an isomer, ester, or ether is a substance listed in Schedule  
3 II if the existence of the isomer, ester, ether, or salt is possible within the specific chemical  
4 designation.

5           (d) A substance is listed in Schedule II if the substance includes a material,  
6 compound, mixture, or preparation that contains any quantity of the following substances  
7 having a potential for abuse associated with a stimulant effect on the central nervous  
8 system:

9           (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;

10           (2) phenmetrazine and its salts;

11           (3) a substance that contains any methamphetamine, including salts,  
12 optical isomers, and salts of its optical isomers, in combination with one or more active  
13 nonnarcotic ingredients in recognized therapeutic amounts;

14           (4) methylphenidate; [and]

15           (5) methamphetamine, its salts, optical isomers, and salts of optical  
16 isomers; AND

17           **(6) LISDEXAMFETAMINE, ITS SALTS, ISOMERS, AND SALTS OF**  
18 **ISOMERS.**

19           (e) (1) Unless specifically excepted under this subtitle or listed in another  
20 schedule, a substance is listed in Schedule II if the substance includes a material,  
21 compound, mixture, or preparation that contains any quantity of the following substances  
22 having a depressant effect on the central nervous system:

23           (i) amobarbital;

24           **(II) GLUTETHIMIDE;**

25           [(ii)] **(III)** secobarbital;

26           [(iii)] **(IV)** pentobarbital;

27           [(iv)] **(V)** phencyclidine;

28           [(v)] **(VI)** 1-(1-phenylcyclohexyl) piperidine;

29           [(vi)] **(VII)** 1-phenylcyclohexylamine; and

30           [(vii)]**(VIII)** 1-piperidinocyclohexanecarbonitrile.

1 (2) Unless specifically excepted under this subtitle or listed in another  
2 schedule, a salt, isomer, or salt of an isomer of a substance listed in this subsection is  
3 included in Schedule II if the existence of the salt, isomer, or salt of an isomer is possible  
4 within the specific chemical designation.

5 (f) The Department may not add a substance to Schedule II under § 5–202 of this  
6 title unless the Department finds:

7 (1) a high potential for abuse of the substance;

8 (2) currently accepted medical use of the substance in the United States,  
9 or currently accepted medical use with severe restrictions; and

10 (3) evidence that abuse of the substance may lead to severe psychological  
11 or physical dependence.

12 5–404.

13 (a) Schedule III consists of each controlled dangerous substance:

14 (1) listed in this section;

15 (2) added to Schedule III by the Department under § 5–202(b) of this title;  
16 or

17 (3) designated as a Schedule III controlled dangerous substance by the  
18 federal government unless the Department objects under § 5–202(f) of this title.

19 (b) (1) Substances listed in Schedule III include:

20 (i) nalorphine; and

21 (ii) except as provided in paragraph (2) of this subsection, an  
22 anabolic steroid consisting of a material, compound, or preparation that includes:

23 1. **13BETA-ETHYL-17BETA-HYDROXYGON-4-EN-3-**  
24 **ONE;**

25 2. **17ALPHA-METHYL-3ALPHA,17BETA-DIHYDROXY-**  
26 **5ALPHA-ANDROSTANE;**

27 3. **17ALPHA-METHYL-3BETA,17BETA-**  
28 **DIHYDROXYANDROST-4-ENE;**

29 4. **17ALPHA-METHYL-4-HYDROXYNANDROLONE;**

- 1                                   **5.    17ALPHA-METHYL-DELTA1-**  
2 **DIHYDROTESTOSTERONE;**
- 3                                   **6.    19-NOR-4,9(10)-ANDROSTADIENEDIONE;**
- 4                                   **7.    ~~19-NOR-4-ANDROSTENEDIOL~~ 19-NOR-4-**  
5 **ANDROSTENEDIOL;**
- 6                                   **8.    19-NOR-4-ANDROSTENEDIONE;**
- 7                                   **9.    19-NOR-5-ANDROSTENEDIOL;**
- 8                                   **10.   19-NOR-5-ANDROSTENEDIONE;**
- 9                                   **11.   1-ANDROSTENEDIOL;**
- 10                                  **12.   1-ANDROSTENEDIONE;**
- 11                                  **13.   3ALPHA,17BETA-DIHYDROXY-5-ALPHA-**  
12 **ANDROSTANE;**
- 13                                  **14.   4-ANDROSTENEDIOL (4-AD);**
- 14                                  **15.   4-ANDROSTENEDIONE;**
- 15                                  **16.   4-HYDROXY-19-NORTESTOSTERONE;**
- 16                                  **17.   4-HYDROXYTESTOSTERONE;**
- 17                                  **18.   5-ANDROSTENEDIONE;**
- 18                                  **19.   BOLASTERONE;**
- 19                                  **[1.] 20.    boldenone;**
- 20                                  **21.   BOLDIONE;**
- 21                                  **22.   CALUSTERONE;**
- 22                                  **[2.] 23.    chlorotestosterone;**
- 23                                  **[3.] 24.    clostebol;**
- 24                                  **[4.] 25.    dehydrochlormethyltestosterone;**

**26. DESOXYMETHYLTESTOSTERONE;****[5.] 27.** dihydrotestosterone;**[6.] 28.** drostanolone;**[7.] 29.** ethylestroenol;**[8.] 30.** fluoxymesterone;**[9.] 31.** formobulone;**32. FURAZABOL;****[10.] 33.** mesterolone;**[11.] 34.** methandienone;**[12.] 35.** methandranone;**[13.] 36.** methandriol;**[14.] 37.** methandrostenolone;**38. METHASTERONE;****[15.] 39.** methenolone;**40. METHYLDIENOLONE;****[16.] 41.** methyltestosterone;**42. METHYLTRIENOLONE;****[17.] 43.** mibolerone;**[18.] 44.** nandrolone;**45. NORCLOSTEBOL;****[19.] 46.** norethandrolone;**47. NORMETHANDROLONE;**

1 [20.] 48. oxandrolone;

2 [21.] 49. oxymesterone;

3 [22.] 50. oxymetholone;

4 51. PROSTANOZOL;

5 [23.] 52. stanolone;

6 [24.] 53. stanozolol;

7 54. STENBOLONE;

8 [25.] 55. testolactone;

9 [26.] 56. testosterone;

10 57. TETRAHYDROGESTRINONE;

11 [27.] 58. trenbolone; and

12 [28.] 59. any isomer, ester, salt, or derivative of a substance

13 listed in this paragraph.

14 (2) The following substances are not included in Schedule III:

15 (i) an estrogen, progestin, or corticosteroid; or

16 (ii) a substance covered by paragraph (1) of this subsection if:

17 1. expressly intended for administration through implants to  
18 cattle or other nonhuman species; and

19 2. approved for that use by the Food and Drug  
20 Administration.

21 (c) (1) Unless listed in another schedule, a substance is listed in Schedule III  
22 if the substance includes a material, compound, mixture, or preparation that contains any  
23 quantity of the following substances having a stimulant effect on the central nervous  
24 system:

25 (i) benzphetamine;

26 (ii) chlorphentermine;



1 (iii) clortermine;

2 (iv) mazindol; and

3 (v) phendimetrazine.

4 (2) Subject to paragraph (3) of this subsection, substances in Schedule III  
5 include:

6 (i) a salt of a substance listed in this subsection;

7 (ii) an optical, position, or geometric isomer of a substance listed in  
8 this subsection; or

9 (iii) a salt of an isomer of a substance listed in this subsection.

10 (3) Unless listed in another schedule, a salt, isomer, or salt of an isomer  
11 described in paragraph (2) of this subsection may be included in Schedule III only if the  
12 existence of the salts, isomers, and salts of isomers is possible within the specific chemical  
13 designation.

14 (d) Unless listed in another schedule, a substance is listed in Schedule III if the  
15 substance includes a material, compound, mixture, or preparation that contains any  
16 quantity of the following substances having a potential for abuse associated with a  
17 depressant effect on the central nervous system:

18 (1) except those substances that are specifically listed in other schedules,  
19 a substance that contains any quantity of a derivative of barbituric acid, or a salt of a  
20 derivative of a barbituric acid;

21 **(2) APROBARBITAL;**

22 **(3) BUTABARBITAL (SECBUTABARBITAL);**

23 **(4) BUTALBITAL (FIORINAL);**

24 **(5) BUTOBARBITAL (BUTETHAL);**

25 **[(2)] (6) chlorhexadol;**

26 **[(3) glutethimide;]**

27 **(7) EMBUTRAMIDE;**

28 **(8) GAMMA HYDROXYBUTYRIC ACID PREPARATIONS;**

- 1            [(4) (9)     lysergic acid;
- 2            [(5) (10)    lysergic acid amide;
- 3            [(6) (11)    methyprylon;
- 4            [(7) (12)    pentazocine;
- 5            (13) PERAMPANEL (FYCOMPA);
- 6            [(8) (14)    sulfondiethylmethane;
- 7            [(9) (15)    sulfonethylmethane; [and]
- 8            [(10) (16)   sulfonmethane;
- 9            (17) ~~TALBUAL~~ TALBUTAL;
- 10           (18) THIAMYLAL;
- 11           (19) THIOPENTAL; AND
- 12           (20) VINBARBITAL.

13           (e) (1) Substances listed in Schedule III include a material, compound,  
14 mixture, or preparation that contains limited quantities of any of these narcotic drugs or  
15 their salts:

16                    (i) not more than 1.80 grams of codeine per 100 milliliters or not  
17 more than 90 milligrams per dosage unit, with an equal or greater quantity of an  
18 isoquinoline alkaloid of opium;

19                    (ii) not more than 1.80 grams of codeine per 100 milliliters or not  
20 more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients  
21 in recognized therapeutic amounts;

22                    (iii) not more than 300 milligrams of dihydrocodeinone per 100  
23 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater  
24 quantity of an isoquinoline alkaloid of opium;

25                    (iv) not more than 300 milligrams of dihydrocodeinone per 100  
26 milliliters or not more than 15 milligrams per dosage unit, with one or more active,  
27 nonnarcotic ingredients in recognized therapeutic amounts;

1 (v) not more than 1.80 grams of dihydrocodeine per 100 milliliters  
2 or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic  
3 ingredients in recognized therapeutic amounts;

4 (vi) not more than 300 milligrams of ethylmorphine per 100  
5 milliliters or not more than 15 milligrams per dosage unit, with one or more active,  
6 nonnarcotic ingredients in recognized therapeutic amounts;

7 (vii) not more than 500 milligrams of opium per 100 milliliters or per  
8 100 grams, or not more than 25 milligrams per dosage unit, with one or more active,  
9 nonnarcotic ingredients in recognized therapeutic amounts;

10 (viii) not more than 100 milligrams of opium per 100 milliliters or per  
11 100 grams, or not more than 5 milligrams per dosage unit; [and]

12 (ix) not more than 50 milligrams of morphine per 100 milliliters or  
13 per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic  
14 amounts; AND

15 (X) BUPRENORPHINE.

16 (2) Substances listed in Schedule III include a compound, mixture, or  
17 preparation or salt of a compound, mixture, or preparation and another active medicinal  
18 ingredient that is not listed in another schedule and that contains:

19 (i) amobarbital;

20 (ii) secobarbital; or

21 (iii) pentobarbital.

22 (3) If not combined with one or more active medicinal ingredients that are  
23 listed in another schedule, substances listed in Schedule III include a suppository dosage  
24 form or salt of a suppository dosage that contains:

25 (i) amobarbital;

26 (ii) secobarbital; or

27 (iii) pentobarbital.

28 (f) Substances listed in Schedule III include:

29 (1) dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin  
30 capsule in a U.S. Food and Drug Administration–approved product; [and]

1 (2) ketamine, its salts, isomers, and salts of isomers;

2 (3) **FIORICET (CONTAINING BUTALBITAL, ACETOMINOPHEN, AND**  
3 **CAFFEINE).**

4 (g) The Department may not add a substance to Schedule III under § 5–202 of  
5 this title unless the Department finds:

6 (1) a potential for abuse of the substance that is less than that for the  
7 substances listed in Schedule I and Schedule II;

8 (2) well documented and approved medical use of the substance in the  
9 United States; and

10 (3) evidence that abuse of the substance may lead to moderate or low  
11 physical dependence or high psychological dependence.

12 5–405.

13 (a) Schedule IV consists of each controlled dangerous substance:

14 (1) listed in this section;

15 (2) added to Schedule IV by the Department under § 5–202(b) of this title;  
16 or

17 (3) designated as a Schedule IV controlled dangerous substance by the  
18 federal government unless the Department objects under § 5–202(f) of this title.

19 (b) Substances listed in Schedule IV include a material, compound, mixture, or  
20 preparation that contains any quantity of the following substances having a potential for  
21 abuse associated with a depressant effect on the central nervous system:

22 (1) **ALFAXALONE;**

23 (2) **ALPRAZOLAM;**

24 [(1)] (3) barbital;

25 [(2)] (4) bromazepam;

26 (5) **BUTORPHANOL;**

27 [(3)] (6) camazepam;

28 (7) **CARISOPRODOL;**

- 1           **(8) CATHINE +/- (NORPSEUDOEPEDRINE);**
- 2           **[(4) (9) chloral betaine;**
- 3           **[(5) (10) chloral hydrate;**
- 4           **[(6) ethchlorvynol;]**
- 5           **[(7) (11) chlordiazepoxide;**
- 6           **[(8) (12) clobazam;**
- 7           **[(9) (13) clonazepam;**
- 8           **[(10) (14) clorazepate;**
- 9           **[(11) (15) clotiazepam;**
- 10          **[(12) (16) cloxazolam;**
- 11          **[(13) (17) delorazepam;**
- 12          **(18) DEXFENFLURAMINE;**
- 13          **(19) DEXTROPROPOXYPHENE DOSAGE FORMS;**
- 14          **[(14) (20) diazepam;**
- 15          **(21) DICHLORALPHENAZONE;**
- 16          **(22) ELUXADOLINE (VIBERZI);**
- 17          **[(15) (23) estazolam;**
- 18          **(24) ETHCHLORVYNOL;**
- 19          **[(16) (25) ethinamate;**
- 20          **[(17) (26) ethylloflazepate;**
- 21          **(27) FENCAMFAMIN;**
- 22          **(28) FENPROPOREX;**

- 1            [(18)] **(29)** fludiazepam;
- 2            [(19)] **(30)** flunitrazepam;
- 3            [(20)] **(31)** flurazepam;
- 4            [(21)] **(32)** halazepam;
- 5            [(22)] **(33)** haloxazolam;
- 6            [(23)] **(34)** ketazolam;
- 7            [(24)] **(35)** loprazolam;
- 8            [(25)] **(36)** lorazepam;
- 9            [(26)] **(37)** lormetazepam;
- 10           [(27)] **(38)** mebutamate;
- 11           [(28)] **(39)** medazepam;
- 12           **(40) MEFENOREX;**
- 13           [(29)] **(41)** methohexital;
- 14           [(30)] **(42)** meprobamate;
- 15           [(31)] **(43)** methylphenobarbital;
- 16           **(44) MIDAZOLAM;**
- 17           **(45) MODAFINIL;**
- 18           [(32)] **(46)** nimetazepam;
- 19           [(33)] **(47)** nitrozepam;
- 20           [(34)] **(48)** nordiazepam;
- 21           [(35)] **(49)** oxazepam;
- 22           [(36)] **(50)** oxazolam;
- 23           [(37)] **(51)** paraldehyde;

- 1            [(38)] **(52)** petrichloral;
- 2            [(39)] **(53)** phenobarbital;
- 3            [(40)] **(54)** pinazepam;
- 4            **(55)** ~~PIPRADNOL~~ PIPRADROL;
- 5            [(41)] **(56)** prazepam;
- 6            **(57)** QUAZEPAM;
- 7            **(58)** SIBUTRAMINE;
- 8            **(59)** SPA (LEFETAMINE);
- 9            **(60)** SUVOREXANT (BELSOMRA);
- 10           [(42)] **(61)** temazepam;
- 11           [(43)] **(62)** tetrazepam; [and]
- 12           **(63)** TRAMADOL;
- 13           [(44)] **(64)** triazolam;
- 14           **(65)** ~~ZALEPION~~ ZALEPLON (SONATA);
- 15           **(66)** ZOLPIDEM (AMBIEN); AND
- 16           **(67)** ZOPICLONE (LUNESTA).

17           (c) Substances listed in Schedule IV include:

- 18           (1) a material, compound, mixture, or preparation that contains  
19 fenfluramine; and
- 20           (2) if its existence is possible:
- 21           (i) a salt of fenfluramine;
- 22           (ii) an optical, position, or geometric isomer of fenfluramine; and
- 23           (iii) a salt of an isomer of fenfluramine.

1 (d) Substances listed in Schedule IV include a material, compound, mixture, or  
2 preparation that contains any quantity of the following substances having a potential for  
3 abuse associated with a stimulant effect on the central nervous system:

4 (1) diethylpropion;

5 (2) pemoline, including organometallic complexes and their chelates; and

6 (3) phentermine.

7 (e) By regulation, the Department may exempt from this section a compound,  
8 mixture, or preparation that contains a depressant substance listed in subsection (b) of this  
9 section if:

10 (1) the compound, mixture, or preparation contains an active medicinal  
11 ingredient that does not have a depressant effect on the central nervous system; and

12 (2) the admixtures are included in combinations, quantity, proportion, or  
13 concentration that vitiate the potential for abuse of the substances that have a depressant  
14 effect on the central nervous system.

15 (f) The Department may not add a substance to Schedule IV under § 5–202 of  
16 this title unless the Department finds that:

17 (1) the substance has a low potential for abuse relative to the substances  
18 listed in Schedule III;

19 (2) the substance has currently accepted medical use in treatment in the  
20 United States; and

21 (3) abuse of the substance may lead to limited physical dependence or  
22 psychological dependence relative to the substances in Schedule III.

23 5–406.

24 (a) Schedule V consists of each controlled dangerous substance:

25 (1) listed in this section;

26 (2) added to Schedule V by the Department under § 5–202(b) of this title;  
27 or

28 (3) designated as a Schedule V controlled dangerous substance by the  
29 federal government unless the Department objects under § 5–202(f) of this title.



1 (b) A substance is listed in Schedule V if the substance includes a compound,  
2 mixture, or preparation that contains the following [quantities of] narcotic drugs or their  
3 salts:

4 (1) (i) not more than 200 milligrams of codeine per 100 milliliters or per  
5 100 grams;

6 (ii) not more than 100 milligrams of dihydrocodeine per 100  
7 milliliters or per 100 grams;

8 (iii) not more than 50 milligrams of ethylmorphine per 100 milliliters  
9 or per 100 grams;

10 (iv) not more than 2.5 milligrams of diphenoxylate and not less than  
11 25 micrograms of atropine sulfate per dosage unit; [or]

12 [(v) unless specifically excepted under this subtitle, or unless listed in  
13 another schedule, any material, compound, mixture, or preparation containing  
14 buprenorphine or its salt; and]

15 (V) BRIVARACETAM;

16 (VI) DIFENOXIN PREPARATIONS 0.5MG/25UG ATSO4/DU  
17 (MOTOFEN);

18 (VII) EZOGABINE (POTIGA);

19 (VIII) LACOSAMIDE (VIMPAT);

20 (IX) PREGABALIN (LYRICA); OR

21 (X) PYROVALERONE; AND

22 (2) nonnarcotic active medicinal ingredients in sufficient proportion to  
23 confer on the compound, mixture, or preparation valuable medicinal qualities other than  
24 those possessed by the narcotic drug alone.

25 (c) The Department may not add a substance to Schedule V under § 5–202 of this  
26 title unless the Department finds:

27 (1) the substance has a low potential for abuse relative to the substances  
28 listed in Schedule IV;

29 (2) the substance has currently accepted medical use in the United States;  
30 and

1 (3) abuse of the substance may lead to limited physical dependence or  
2 psychological dependence liability relative to the substances listed in Schedule IV.

3 **5-908.**

4 (A) THE DEPARTMENT MAY IMPOSE A CIVIL PENALTY IN AN AMOUNT NOT  
5 EXCEEDING \$1,000 FOR EACH VIOLATION OF THIS TITLE.

6 (B) THE DEPARTMENT SHALL ADOPT REGULATIONS TO SET STANDARDS  
7 FOR THE IMPOSITION OF PENALTIES UNDER THIS SECTION.

8 (C) THE DEPARTMENT SHALL REMIT A PENALTY IMPOSED UNDER THIS  
9 SECTION TO THE GENERAL FUND OF THE STATE.

10 **Article – Health – General**

11 21-1113.

12 (a) (1) In this section the following terms have the meanings indicated.

13 (2) “Authorized prescriber” means a licensed dentist, licensed physician,  
14 licensed podiatrist, licensed veterinarian, certified nurse midwife to the extent permitted  
15 under § 8-601 of the Health Occupations Article, certified nurse practitioner to the extent  
16 permitted under § 8-508 of the Health Occupations Article, or other individual authorized  
17 by law to prescribe prescription or nonprescription drugs or devices.

18 (3) “Board” means a health occupation licensing board authorized to issue  
19 a permit, license, or certificate under the Health Occupations Article.

20 (4) (i) “Controlled dangerous substance” means a drug, substance, or  
21 immediate precursor listed in Schedule I through Schedule V in Title 5 of the Criminal Law  
22 Article.

23 (ii) “Controlled dangerous substance” does not include tobacco or a  
24 distilled spirit, wine, or malt beverage.

25 (5) “Drug” means a prescription or nonprescription drug.

26 (6) “Nonprescription drug” means a drug which may be sold without a  
27 prescription and which is labeled for consumer use in accordance with the requirements of  
28 the laws and regulations of this State and the federal government.

29 (7) “Permit holder” means a holder of, or applicant for:

1 (i) A pharmacy permit[, manufacturer’s permit,] or distributor’s  
2 permit issued by the State Board of Pharmacy under Title 12 of the Health Occupations  
3 Article; [or]

4 (ii) A dispensing permit issued by a board under the authority of §  
5 12–102(c)(2) of the Health Occupations Article; OR

6 (iii) **A CONTROLLED DANGEROUS SUBSTANCES REGISTRATION**  
7 **ISSUED BY THE OFFICE OF CONTROLLED SUBSTANCES ADMINISTRATION UNDER §**  
8 **5–301(A)(1) OF THE CRIMINAL LAW ARTICLE.**

9 (8) “Prescription drug” means a drug that under § 21–220 of this title may  
10 be dispensed only on the prescription of a health practitioner who is authorized by law to  
11 prescribe the drug.

12 (b) (1) The Department may issue an order of impoundment and immediately  
13 impound drugs, **BULK POWDERS AND CHEMICALS**, or prescription records of a permit  
14 holder or an authorized prescriber if:

15 (i) A permit holder’s permit or authorized prescriber’s license has  
16 expired or has been revoked or suspended;

17 (ii) An application for a permit or license has been denied;

18 (iii) A board has:

19 1. Determined that the permit holder or authorized  
20 prescriber failed to comply with a board order, letter of surrender, or law regarding the  
21 disposition of drugs, **BULK POWDERS AND CHEMICALS**, or prescription records; and

22 2. Requested that the Department impound the drugs, **BULK**  
23 **POWDERS AND CHEMICALS**, or prescription records;

24 (iv) The drugs **OR BULK POWDERS AND CHEMICALS** pose an  
25 imminent threat to the public health, safety, or welfare; or

26 (v) The confidentiality of the prescription records is in imminent  
27 danger of being compromised.

28 (2) The Department may not impound the drugs, **BULK POWDERS AND**  
29 **CHEMICALS**, or prescription records of a permit holder or authorized prescriber who is in  
30 compliance with a board order or law specifically providing for the manner of the disposition  
31 of drugs, **BULK POWDERS AND CHEMICALS**, or prescription records.

32 (c) (1) Except as otherwise provided in paragraph (2) of this subsection, the  
33 Department shall:

1 (i) Attempt to serve written notice of an impoundment on the permit  
2 holder or authorized prescriber;

3 (ii) Provide the permit holder or authorized prescriber with an  
4 opportunity to avoid impoundment by allowing the permit holder or authorized prescriber  
5 to dispose of the drugs, **BULK POWDERS AND CHEMICALS**, or prescription records in a  
6 manner acceptable to the Department;

7 (iii) Provide the permit holder or authorized prescriber with an  
8 opportunity prior to impoundment to review the nature, type, and amount of information  
9 upon which the Department issued the impoundment order; and

10 (iv) Provide the permit holder or authorized prescriber with an  
11 opportunity to avoid impoundment by providing the Department with information upon  
12 which the Department could reasonably conclude that the impoundment is not warranted.

13 (2) If drugs **OR BULK POWDERS AND CHEMICALS** pose an imminent  
14 threat to the public health, safety, or welfare, or if the confidentiality of prescription records  
15 is in imminent danger of being compromised, the Department may:

16 (i) Issue an impoundment order; and

17 (ii) Immediately impound drugs, **BULK POWDERS AND**  
18 **CHEMICALS**, or prescription records without prior notice to the permit holder or authorized  
19 prescriber.

20 (d) An order of impoundment constitutes a final order subject to judicial review  
21 under the State Administrative Procedure Act.

22 (e) The Department shall provide the permit holder or authorized prescriber with  
23 a list of all drugs, **BULK POWDERS AND CHEMICALS**, and prescription records impounded.

24 (f) The Department may charge reasonable fees to recover the costs of the  
25 collection, storage, and disposition of drugs, **BULK POWDERS AND CHEMICALS**, or  
26 prescription records.

27 (g) The Department shall adopt regulations governing the disposition of  
28 impounded drugs, **BULK POWDERS AND CHEMICALS**, and prescription records.

29 (h) Prior to issuing an order of impoundment, the Department, with the approval  
30 of the Board of Pharmacy, shall develop regulations concerning:

31 (1) The nature, type, and amount of information upon which the  
32 Department may rely to issue an order of impoundment;

1 (2) The level of investigation the Department must pursue to verify the  
2 information upon which the order of impoundment was based under subsection (b)(1)(iv) or  
3 (v) or (c)(2) of this section; and

4 (3) The measures the Department must pursue to attempt service on the  
5 permit holder or authorized prescriber prior to impoundment under subsection (c) of this  
6 section.

7 (i) Prior to destroying or transferring impounded drugs, **BULK POWDERS AND**  
8 **CHEMICALS**, or prescription records, the Department shall publish a notice [for 2  
9 consecutive weeks] **ONCE A WEEK FOR 2 CONSECUTIVE WEEKS** in a [daily] newspaper  
10 that is circulated locally:

11 (1) Stating the date that the drugs, **BULK POWDERS AND CHEMICALS**, or  
12 prescription records will be destroyed or transferred; and

13 (2) Designating a date, time, and location where the drugs, **BULK**  
14 **POWDERS AND CHEMICALS**, or prescription records may be retrieved by the permit holder  
15 or authorized prescriber if certain conditions are met.

16 (j) A board shall immediately notify the Office of Controlled Substances  
17 Administration of the surrender, suspension, or revocation of a permit holder’s permit or  
18 an authorized prescriber’s license.

19 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect  
20 October 1, 2018.

Approved:

\_\_\_\_\_  
Governor.

\_\_\_\_\_  
President of the Senate.

\_\_\_\_\_  
Speaker of the House of Delegates.